Louqin Zhisou Decoction Inhibits Mucus Hypersecretion for Acute Exacerbation of Chronic Obstructive Pulmonary Disease Rats by Suppressing EGFR-PI3K-AKT Signaling Pathway and Restoring Th17/Treg Balance

<div>Lung morphology of each group. (a) Pathological changes in the airway structure (H&amp;E staining magnification ×100 and ×400). Control group showing a normal structure of airway; AECOPD group exhibiting noticeable changes, with thickened airway, loss of cilia, submucosal gland hyperplasia, and hypertrophy; CAM group and LQZS group showing less airway inflammation. (b) Pathological changes in the alveoli (H&amp;E staining magnification ×100). Control group demonstrating regular morphology of alveoli; AECOPD group showing inflammatory cell infiltration, broken alveolar walls, widen alveolar septum, and hyperemia; CAM group and LQZS group showing lower alveolar destruction.</div>

Evidence-Based Complementary and Alternative Medicine

fig1

Figure 1

Figure 1: Louqin Zhisou Decoction Inhibits Mucus Hypersecretion for Acute Exacerbation of Chronic Obstructive Pulmonary Disease Rats by Suppressing EGFR-PI3K-AKT Signaling Pathway and Restoring Th17/Treg Balance 

Figure 1 | Louqin Zhisou Decoction Inhibits Mucus Hypersecretion for Acute Exacerbation of Chronic Obstructive Pulmonary Disease Rats by Suppressing EGFR-PI3K-AKT Signaling Pathway and Restoring Th17/Treg Balance 